NASDAQ:HCWB HCW Biologics Q3 2026 Earnings Date & Estimates $1.12 +0.02 (+1.82%) Closing price 11/2/2026 04:00 PM EasternExtended Trading$1.12 0.00 (0.00%) As of 11/2/2026 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. HCW Biologics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026Conference Call DateNovember 13, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from HCW Biologics in Q3 2026HCW Biologics is expected to post earnings of -$1.35 per share on revenue of $119 thousand. In the same quarter a year earlier HCW Biologics reported -$12.12 per share on revenue of $3.12 thousand. HCW Biologics last reported on August 14, 2026, posting -$11.58 per share and missing the -$1.98 consensus estimate. HCW Biologics has beaten the consensus EPS estimate in 1 of its last 5 quarters.Consensus EstimatesConsensus EPS-$1.35Expected Revenue$119 thousandPrior-Year EPS-$12.12Prior-Year Revenue$3.12 thousandExpected Revenue Growth+3,712.9%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$11.58 (Missed by -$9.60)Last Quarter Revenue$135.57 thousandEPS Beat Rate1 of last 5 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report HCW Biologics Q3 2026 Earnings FAQ When does HCW Biologics report Q3 2026 earnings? HCW Biologics (NASDAQ:HCWB) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is HCW Biologics' Q3 2026 earnings call? HCW Biologics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for HCW Biologics? Analysts expect HCW Biologics to post earnings of -$1.35 per share for Q3 2026. How much revenue is HCW Biologics expected to report? The consensus revenue estimate for HCW Biologics is $119 thousand for Q3 2026. HCW Biologics Earnings HeadlinesHCW Biologics (NASDAQ:HCWB) Stock Rating Upgraded by Wall Street ZenOctober 31 at 1:13 AM | americanbankingnews.comHCW Biologics consensus price target decreased by 73.33% to $8.16October 23, 2026 | msn.comFinancial Legend: “Big trouble ahead …”Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks. | Weiss Ratings (Ad)HCW Biologics Reports FDA Type B Meeting Guidance for HCW11-018b IND Preparation in Solid TumorsOctober 9, 2026 | quiverquant.comQHCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid TumorsOctober 9, 2026 | globenewswire.comHCW Biologics Prices $1.5M Private PlacementSeptember 24, 2026 | rttnews.comSee More HCW Biologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email. Email Address About HCW BiologicsHCW Biologics (NASDAQ:HCWB) (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression. HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression. The company has investigated its candidates in oncology and other diseases involving chronic inflammation. HCW Biologics is headquartered in Miramar, Florida, and conducts its work through research, preclinical and clinical development programs. As a development-stage biotechnology company, its products remain investigational and are subject to clinical testing and regulatory review before they can be marketed.View HCW Biologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another TestAlphabet’s $400 Billion Sell-Off Could Be the Best AI Buying Window Left in 2026Exxon's Refining Profits Soared—Did Chevron Get the Same Windfall?LyondellBasell's Dividend Looks Safer, But a New Risk Could Change ThatUranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Silicon Shock: Intel's 25% Valuation Reset Upcoming Earnings Booking (11/3/2026)Ferrari (11/3/2026)Marathon Petroleum (11/3/2026)Mplx (11/3/2026)Suncor Energy (11/3/2026)Apollo Global Management (11/3/2026)Itau Unibanco (11/3/2026)Amgen (11/3/2026)Pfizer (11/3/2026)Eaton (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
